Potent kratom compound 7-OH is driving a wave of new state regulation

A potent kratom derivative called concentrated 7-hydroxymitragynine, or 7-OH, is spreading alongside traditional kratom leaf products, pushing lawmakers in 36 states to introduce regulation during the 2025 and 2026 sessions. At least 31 states already regulate kratom in some form, from outright bans to age limits and labeling rules, while federal regulators have moved against high-potency synthetic compounds while leaving plain botanical kratom alone.

U.S. poison centers logged 14,449 kratom exposure reports from 2015 through 2025, including 3,434 in 2025 alone, an increase researchers put at roughly 1,200 percent since 2015; reports through June of this year already total 3,190, putting 2026 on pace for a 68 percent jump over last year. The data doesn't distinguish between traditional leaf products and concentrated formulations, which limits what can be concluded about which products are driving the numbers.

Pennsylvania lawmakers are weighing a bill that would let registered retailers sell natural-leaf kratom to adults 21 and older while banning products with more than 0.5% 7-OH; it cleared a House committee unanimously. In Mississippi, police investigating two university students' deaths found the same synthetic kratom-derived product in both cases, though no link to the deaths has been established and toxicology results are pending.

Addiction physicians say 7-OH binds more directly to the same opioid receptor targeted by morphine and fentanyl, making dependence and withdrawal more severe than with traditional kratom. Researchers caution that basic questions about safe dosing, age-related effects, and any therapeutic use remain unanswered for a product sold with essentially no quality control.

The full dispatch is available from the source below.